FDA Advisory Committee Is Sign Of Grim Progress For Ferring’s Nocdurna

Ferring’s nocturia treatment seems headed for another rejection, but a chance to make its case at an advisory panel can be seen as a win for company’s 505(b)(2) desmopressin application.